// Global Analysis Archive
According to the source, Chinese biotech firms’ cross-border outlicensing reached a record US$60 billion in Q1 2026, up 73% year on year. The surge highlights growing multinational appetite for China-origin innovative drug candidates and a deepening integration of China’s biotech sector into global pharma dealmaking.
An explosion at Jiapeng Biotech in Shanxi’s Shanyin County killed eight people, according to CNA citing Chinese state media, with clean-up ongoing and an investigation underway. The incident may intensify safety enforcement and raise operational and environmental risk scrutiny across North China’s industrial base.
Hong Kong, Shenzhen and GBA clinical trial institutions have formalised cooperation to run large-scale trials for two US-developed treatments targeting breast cancer and a degenerative eye disease. The initiative signals a push to operationalise cross-border trial infrastructure and strengthen the Greater Bay Area’s life sciences competitiveness.
According to the source, Chinese biotech firms’ cross-border outlicensing reached a record US$60 billion in Q1 2026, up 73% year on year. The surge highlights growing multinational appetite for China-origin innovative drug candidates and a deepening integration of China’s biotech sector into global pharma dealmaking.
An explosion at Jiapeng Biotech in Shanxi’s Shanyin County killed eight people, according to CNA citing Chinese state media, with clean-up ongoing and an investigation underway. The incident may intensify safety enforcement and raise operational and environmental risk scrutiny across North China’s industrial base.
Hong Kong, Shenzhen and GBA clinical trial institutions have formalised cooperation to run large-scale trials for two US-developed treatments targeting breast cancer and a degenerative eye disease. The initiative signals a push to operationalise cross-border trial infrastructure and strengthen the Greater Bay Area’s life sciences competitiveness.
| ID | Title | Category | Date | Views | |
|---|---|---|---|---|---|
| RPT-3252 | China Biotech Outlicensing Surges to Record as Multinationals Chase Innovative Drug Pipelines | China Biotech | 2026-03-29 | 0 | ACCESS » |
| RPT-841 | Shanxi Biotech Factory Blast Highlights Renewed Industrial Safety Pressure in North China | China | 2026-02-08 | 0 | ACCESS » |
| RPT-5499 | Hong Kong Advances Cross-Border GBA Clinical Trials for US-Developed Cancer and Eye Therapies | Hong Kong | 2024-12-04 | 0 | ACCESS » |